血液检测市场－全球产业规模、份额、趋势、机会、预测：按技术、产品、地区和竞争对手划分，2021-2031年

全球血液筛检市场预计将从 2025 年的 48.8 亿美元成长到 2031 年的 67.6 亿美元，复合年增长率为 5.57%。

该市场涵盖输血前对捐血血浆和血液的严格检测，以检测传染性病原体并确认其适用性。推动这一市场扩张的关键因素包括输血传染病在全球范围内的日益蔓延以及强制执行安全通讯协定的严格监管要求。此外，创伤和外科手术治疗中对血液製品的需求不断增长，也显着推动了更广泛的医疗保健网络对充足筛检能力的需求。

另一方面，先进分子检测平台的高成本对发展中地区预算紧张的医疗系统而言构成了一道进入门槛。儘管高端筛检技术已被证实具有安全性优势，但此经济障碍限制了其应用。根据血液与生物疗法促进协会2025年3月发布的报告，2023年美国采集了1,158万单位红血球，凸显了已开发市场维持血液供应所需的庞大营运规模和巨额资金投入。

市场驱动因素

慢性病和感染疾病的蔓延是血液筛检市场的主要驱动力，需要严格的病原体鑑定以确保输血安全。随着全球病毒量的上升，医疗基础设施亟需实施严格的核酸增幅检查(NAT) 和免疫检测，以便在乙型肝炎、丙型肝炎和爱滋病毒进入血液供应之前将其检测出来。这些疾病死亡率的上升凸显了这项需求。世界卫生组织 (WHO) 于 2024 年 4 月发布的《2024 年全球肝炎报告》显示，2022 年病毒性肝炎导致 130 万人死亡，这进一步强调了提高筛检能力以遏制透过血液製品传播疾病的紧迫性。

此外，全球对输血和捐血的需求不断增长，进一步加剧了市场对高效能、大容量筛检系统的依赖，尤其是在捐血数量波动的情况下。为了优化每一单位采集血液的使用，需要采用自动化系统，以最大限度地减少浪费，并为紧急情况提供快速检测结果。然而，维持充足的血液库存仍然是一项重大挑战。美国红十字会在2024年1月的新闻稿中指出，过去20年捐血人数减少了约40%，凸显了精准筛检以避免浪费的重要性。罗氏公司在2024年报告称，该公司前一年在全球范围内提供了290亿次诊断测试，这就是一个说明诊断需求规模的例子。

市场挑战

先进分子检测系统的高昂成本是全球血液筛检市场的主要阻碍因素，尤其是在新兴市场对经济较为敏感的医疗保健领域。这些飙升的营运成本构成了准入壁垒，阻碍了已开发国家已成为标准做法的高品质筛检技术的广泛应用。因此，资源匮乏地区的检查室往往依赖更便宜但过时的检测技术，甚至完全放弃全面的筛检。这种经济差距直接阻碍了市场发展，限制了自动化设备和先进检测套组的潜在基本客群，实际上将商机限制在了成熟、富裕的医疗保健网路手中。

根据国际输血协会（ISBT）2024年的数据，由于基础建设和资金严重不足，撒哈拉以南非洲地区约有20%的捐血未接受传染病检查。这一数字凸显了成本障碍的严重后果，显示缺乏关键筛检通讯协定的资金，导致全球很大一部分人口无法获得先进的血液安全保障。只要这些资金限制持续存在，发展中地区的市场成长将持续受到严重限制。

市场趋势

扩展血型基因分型技术的兴起正在重塑市场格局，其提供的捐血匹配比标准的ABO和Rh血型相容性检测更为精准。这项发展对于避免需要长期输血的患者（例如镰状细胞贫血症患者）发生同种免疫反应至关重要，因为它能够检测到传统血清学检测通常无法发现的微小抗原突变。随着检查室越来越重视输血安全以减少不利事件，对先进分子分型工具的需求正在迅速成长。例如，Griffols公司在2025年2月公布，其2024年全年销售额增长了10.3%（不计外汇波动的影响），并特别指出其血型分型解决方案业务是关键市场实现两位数增长的主要贡献者。

同时，自动化、高通量筛检系统正成为一个明显的趋势，旨在优化检测流程并应对日益增长的检测工作量。透过将检体製备到结果解读等各个检测阶段整合到一个整合的模组化平台中，血站可以显着减少人为错误和运作成本，同时缩短週转时间。处理大量常规检体的中心实验室对扩充性技术的需求进一步推动了这一趋势。根据罗氏于2025年1月发布的2024财年年度报告，诊断部门的销售额增长了4%，这主要得益于全球范围内高通量分子和免疫诊断解决方案的广泛应用，这些解决方案显着提高了检查室效率。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球血液检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依技术分类（核酸增幅检查（NAT）、酵素连结免疫吸附试验（ELISA）、化学化学冷光免疫检测（CLIA）、酵素免疫分析法（EIA）、次世代定序（NGS）、蛋白质印迹法）
  • 副产品（试剂、仪器）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美血液检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲血液检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区血液检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲血液检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲血液检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球血液检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Abbott
• Roche Diagnostics
• Bio-Rad
• Siemens Healthineers
• Grifols
• Ortho Clinical Diagnostics
• QuidelOrtho
• Thermo Fisher
• DiaSorin
• Beckman Coulter

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Blood Screening Market is projected to expand from USD 4.88 Billion in 2025 to USD 6.76 Billion by 2031, registering a CAGR of 5.57%. This market involves the rigorous examination of donated plasma and blood to detect infectious agents and verify compatibility prior to transfusion procedures. The primary drivers for this expansion include the rising worldwide prevalence of infections transmissible via transfusion and stringent regulatory requirements that enforce safety protocols. Additionally, the growing necessity for blood products in trauma and surgical care significantly fuels the need for substantial screening capacities across extensive healthcare networks.

Conversely, the high costs linked to sophisticated molecular testing platforms present an entry barrier for budget-constrained healthcare systems in developing areas. This financial obstacle restricts the uptake of high-end screening technologies, notwithstanding their demonstrated safety advantages. According to the Association for the Advancement of Blood & Biotherapies in March 2025, 11.58 million units of red blood cells were collected in the United States in 2023, highlighting the massive operational magnitude and financial investment necessary to maintain the blood supply in advanced markets.

Market Driver

The escalating prevalence of chronic and infectious diseases serves as a major stimulant for the blood screening market, requiring strict pathogen identification to guarantee transfusion security. With viral loads rising globally, healthcare infrastructures are urged to adopt rigorous nucleic acid amplification testing (NAT) and immunoassay measures to detect Hepatitis B, Hepatitis C, and HIV prior to their entry into the blood supply. This necessity is emphasized by increasing mortality rates linked to these conditions; according to the World Health Organization's 'Global Hepatitis Report 2024' released in April 2024, viral hepatitis caused 1.3 million deaths in 2022, reinforcing the urgent need for superior screening capabilities to curb transmission via blood products.

Furthermore, the surging global requirement for blood transfusions and donations intensifies the market's dependence on efficient, high-volume screening systems, especially given the fluctuations in donor availability. The imperative to optimize every collected unit promotes the use of automated systems that minimize discard rates and facilitate quick results for emergency cases. However, sustaining sufficient stock remains a major hurdle; the American Red Cross reported in a January 2024 press release that donor numbers have dropped by roughly 40% over the past two decades, leading to a supply crisis that underscores the value of precise screening to avoid waste. To illustrate the scale of diagnostic needs, Roche reported in 2024 that it delivered 29 billion diagnostic tests globally during the previous year.

Market Challenge

The significant costs attached to advanced molecular testing systems act as a major constraint on the Global Blood Screening Market, especially within economically sensitive healthcare sectors in emerging markets. These elevated operational expenses form a substantial barrier to entry, hindering the broad implementation of premium screening technologies that are standard practice in developed countries. As a result, laboratories in resource-poor environments frequently depend on cheaper, outdated testing techniques or skip comprehensive screening altogether. This economic gap directly impedes market progress by restricting the potential customer base for automated instruments and advanced assay kits, effectively limiting revenue opportunities to established, affluent healthcare networks.

Data from the International Society of Blood Transfusion in 2024 revealed that roughly 20% of blood donations in Sub-Saharan Africa went untested for transfusion-transmissible infections due to critical infrastructure and financial limitations. This figure highlights the severe consequences of cost barriers, as the lack of funding for vital screening protocols excludes a large segment of the global population from accessing advanced blood safety measures. As long as these financial constraints continue, the market's growth into developing regions will remain significantly restricted.

Market Trends

The rise of extended blood group genotyping is reshaping the market by facilitating exact donor-recipient matching that exceeds standard ABO and Rh compatibility checks. This evolution is vital for averting alloimmunization in patients requiring chronic transfusions, such as those suffering from sickle cell disease, by detecting minor antigen variations that conventional serology frequently fails to identify. As labs increasingly focus on transfusion safety to reduce adverse events, the demand for sophisticated molecular typing tools has risen sharply. For instance, Grifols reported in February 2025 that it achieved a 10.3% total annual revenue increase at constant currency for 2024, specifically citing its Blood Typing Solutions division as a key contributor with double-digit growth in major markets.

Simultaneously, there is a clear movement toward automated, high-throughput screening systems aimed at optimizing laboratory workflows and handling growing testing loads. By consolidating various assay stages-from sample prep to result interpretation-into unified modular platforms, blood centers can drastically cut manual errors and operating expenses while enhancing turnaround speeds. This trend is reinforced by the necessity for scalable technologies in centralized testing hubs that handle immense volumes of daily samples. According to Roche's 'Annual Report 2024' released in January 2025, Diagnostics Division sales grew by 4%, largely fueled by the robust global adoption of high-throughput molecular and immunodiagnostic solutions that improve lab efficiency.

Key Market Players

• Abbott
• Roche Diagnostics
• Bio-Rad
• Siemens Healthineers
• Grifols
• Ortho Clinical Diagnostics
• QuidelOrtho
• Thermo Fisher
• DiaSorin
• Beckman Coulter

Report Scope

In this report, the Global Blood Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Blood Screening Market, By Technology

• Nucleic Acid Amplification Test (NAT)
• ELISA
• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
• Next Generation Sequencing (NGS)
• Western Blotting

Blood Screening Market, By Product

• Reagent
• Instrument

Blood Screening Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Blood Screening Market.

Available Customizations:

Global Blood Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Blood Screening Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Nucleic Acid Amplification Test (NAT), ELISA, Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA), Next Generation Sequencing (NGS), Western Blotting)
  • 5.2.2. By Product (Reagent, Instrument)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Blood Screening Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Blood Screening Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product
  • 6.3.2. Canada Blood Screening Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product
  • 6.3.3. Mexico Blood Screening Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product

7. Europe Blood Screening Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Blood Screening Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product
  • 7.3.2. France Blood Screening Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product
  • 7.3.3. United Kingdom Blood Screening Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product
  • 7.3.4. Italy Blood Screening Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product
  • 7.3.5. Spain Blood Screening Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product

8. Asia Pacific Blood Screening Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Blood Screening Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product
  • 8.3.2. India Blood Screening Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product
  • 8.3.3. Japan Blood Screening Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product
  • 8.3.4. South Korea Blood Screening Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product
  • 8.3.5. Australia Blood Screening Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product

9. Middle East & Africa Blood Screening Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Blood Screening Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product
  • 9.3.2. UAE Blood Screening Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product
  • 9.3.3. South Africa Blood Screening Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product

10. South America Blood Screening Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Product
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Blood Screening Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product
  • 10.3.2. Colombia Blood Screening Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product
  • 10.3.3. Argentina Blood Screening Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Blood Screening Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Roche Diagnostics
• 15.3. Bio-Rad
• 15.4. Siemens Healthineers
• 15.5. Grifols
• 15.6. Ortho Clinical Diagnostics
• 15.7. QuidelOrtho
• 15.8. Thermo Fisher
• 15.9. DiaSorin
• 15.10. Beckman Coulter

16. Strategic Recommendations

17. About Us & Disclaimer